Sleep disorders in chronic obstructive pulmonary disease: Etiology, impact, and management

Journal of Clinical Sleep Medicine

Volumn 11, Issue 3, 2015, Pages 259-270

  Budhiraja, Rohit ^a   Siddiqi, Tauseef A ^b   Quan, Stuart F ^b,c  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

COPD; Hypoventilation; Insomnia; Obstructive sleep apnea; Restless legs syndrome

Indexed keywords

BRONCHODILATING AGENT; DOXEPIN; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; IRON; LEVODOPA; LEVOTHYROXINE; MELATONIN; MIANSERIN; MIRTAZAPINE; OLANZAPINE; OXYGEN; PRAMIPEXOLE; PREGABALIN; TEMAZEPAM;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE THERAPY; HEADACHE; HUMAN; HYPERCAPNIA; HYPOVENTILATION; HYPOXEMIA; INSOMNIA; MEDICARE; META ANALYSIS (TOPIC); OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP DISORDERED BREATHING; COMPLICATION; HYPOXIA; SLEEP APNEA, OBSTRUCTIVE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP WAKE DISORDERS;

HUMANS; HYPOXIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESTLESS LEGS SYNDROME; SLEEP APNEA, OBSTRUCTIVE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP WAKE DISORDERS;

EID: 84924869418     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.4540     Document Type: Review

References (182)

1. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987;91:540-6.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73.
3. Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 2011;34:859-67.
4. Budhiraja R, Parthasarathy S, Budhiraja P, Habib MP, Wendel C, Quan SF. Insomnia in patients with COPD. Sleep 2012;35:369-75.
5. Budhiraja P, Budhiraja R, Goodwin JL, et al. Incidence of restless legs syndrome and its correlates. J Clin Sleep Med 2012;8:119-24.
6. Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med 2011;12:367-72.
7. Emilsson OI, Janson C, Benediktsdóttir B, Júlíusson S, Gíslason T. Nocturnal gastroesophageal reflux, lung function and symptoms of obstructive sleep apnea: results from an epidemiological survey. Respir Med 2012;106:459-66.
8. Budhiraja R, Quan SF, Punjabi NM, Drake CL, Dickman R, Fass R. Power spectral analysis of the sleep electroencephalogram in heartburn patients with or without gastroesophageal reflux disease: a feasibility study. J Clin Gastroenterol 2010;44:91-6.
9. Fleetham J, West P, Mezon B, Conway W, Roth T, Kryger M. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982;126:429-33.
10. Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med 2012;13:476-83.
11. Klink ME, Dodge R, Quan SF. The relation of sleep complaints to respiratory symptoms in a general population. Chest 1994;105:151-4.
12. Calverley PM, Brezinova V, Douglas NJ, Catterall JR, Flenley DC. The effect of oxygenation on sleep quality in chronic bronchitis and emphysema. Am Rev Respir Dis 1982;126:206-10.
13. Goldstein RS, Ramcharan V, Bowes G, McNicholas WT, Bradley D, Phillipson EA. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 1984;310:425-9.
14. McKeon JL, Murree-Allen K, Saunders NA. Supplemental oxygen and quality of sleep in patients with chronic obstructive lung disease. Thorax 1989;44:184-8.
15. Aras G, Kadakal F, Purisa S, Kanmaz D, Aynaci A, Isik E. Are we aware of restless legs syndrome in COPD patients who are in an exacerbation period? Frequency and probable factors related to underlying mechanism. COPD 2011;8:437-43.
16. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 2010;25:1209-21.
17. Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD-a review. Respir Med 2011;105:1422-33.
18. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a crosssectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.
19. Sundh J, Ställberg B, Lisspers K, Montgomery SM, Janson C. Co-morbidity, body mass index and quality of life in COPD using the Clinical COPD Questionnaire. COPD 2011;8:173-81.
20. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
21. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev 2010;14:9-15.
22. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010;14:19-31.
23. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998;60:610-5.
24. Haynes SN, Adams A, Franzen M. The effects of presleep stress on sleeponset insomnia. J Abnorm Psychol 1981;90:601-6.
25. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001;86:3787-94.
26. Bonnet MH, Arand DL. 24-hour metabolic rate in insomniacs and matched normal sleepers. Sleep 1995;18:581-8.
27. Nofzinger EA, Buysse DJ, Germain A, Price JC, Miewald JM, Kupfer DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004;161:2126-8.
28. Sica AL, Greenberg HE, Ruggiero DA, Scharf SM. Chronic-intermittent hypoxia: a model of sympathetic activation in the rat. Respir Physiol 2000;121:173-84.
29. Calbet JA. Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans. J Physiol 2003;551(Pt 1):379-86.
30. Hardy JC, Gray K, Whisler S, Leuenberger U. Sympathetic and blood pressure responses to voluntary apnea are augmented by hypoxemia. J Appl Physiol 1994;77:2360-5.
31. Gilmartin GS, Lynch M, Tamisier R, Weiss JW. Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2010;299:H925-31.
32. Oikawa S, Hirakawa H, Kusakabe T, Nakashima Y, Hayashida Y. Autonomic cardiovascular responses to hypercapnia in conscious rats: the roles of the chemo- and baroreceptors. Auton Neurosci 2005;117:105-14.
33. Morgan BJ, Crabtree DC, Palta M, Skatrud JB. Combined hypoxia and hypercapnia evokes long-lasting sympathetic activation in humans. J Appl Physiol 1995;79:205-13.
34. Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Invest 1991;87:1953-7.
35. Holloway RA, Donnelly LE. Immunopathogenesis of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2013;19:95-102.
36. Loukides S, Bartziokas K, Vestbo J, Singh D. Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr Drug Targets 2013;14:235-45.
37. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal 2013;18:1956-71.
38. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012;122:2749-55.
39. Wu KL, Chan SH, Chan JY. Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J Neuroinflammation 2012;9:212.
40. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004;25:363-70.
41. Jensen-Urstad M, Jensen-Urstad K, Ericson M, Johansson J. Heart rate variability is related to leucocyte count in men and to blood lipoproteins in women in a healthy population of 35-year-old subjects. J Intern Med 1998;243:33-40.
42. van Gestel AJ, Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). J Thorac Dis 2010;2:215-22.
43. van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov Med 2012;14:359-68.
44. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005;128:3618-24.
45. Heindl S, Lehnert M, Criée CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001;164:597-601.
46. Bratel T, Wennlund A, Carlström K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med 2000;94:1221-8.
47. Corbo GM, Inchingolo R, Sgueglia GA, Lanza G, Valente S. C-reactive protein, lung hyperinflation and heart rate variability in chronic obstructive pulmonary disease: a pilot study. COPD 2013;10:200-7.
48. van Gestel AJ, Kohler M, Steier J, et al. Cardiac autonomic function and cardiovascular response to exercise in patients with chronic obstructive pulmonary disease. COPD 2012;9:160-5.
49. Skyba P, Joppa P, Orolín M, Tkácová R. Blood pressure and heart rate variability response to noninvasive ventilation in patients with exacerbations of chronic obstructive pulmonary disease. Physiol Res 2007;56:527-33.
50. Yoshimura K, Maekura R, Hiraga T, et al. Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis 2012;7:109-17.
51. Johansson JK, Kronholm E, Jula AM. Variability in home-measured blood pressure and heart rate: associations with self-reported insomnia and sleep duration. J Hypertens 2011;29:1897-905.
52. Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension 2012;60:929-35.
53. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care 2009;32:1980-5.
54. Kachi Y, Nakao M, Takeuchi T, Yano E. Association between insomnia symptoms and hemoglobin A1c level in Japanese men. PLoS One 2011;6:e21420.
55. Fernandez-Mendoza J, Calhoun S, Bixler EO, et al. Insomnia with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study. Sleep 2010;33:459-65.
56. Nakazaki C, Noda A, Koike Y, Yamada S, Murohara T, Ozaki N. Association of insomnia and short sleep duration with atherosclerosis risk in the elderly. Am J Hypertens 2012;25:1149-55.
57. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation 2011;124:2073-81.
58. Vgontzas AN, Liao D, Pejovic S, et al. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep 2010;33:1159-64.
59. Hublin C, Partinen M, Koskenvuo M, Kaprio J. Heritability and mortality risk of insomnia-related symptoms: a genetic epidemiologic study in a populationbased twin cohort. Sleep 2011;34:957-64.
60. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504.
61. Doghramji K. The evaluation and management of insomnia. Clin Chest Med 2010;31:327-39.
62. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract 2012;13:40.
63. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 2006;29:1415-9.
64. Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev 2005;25:559-92.
65. Kapella MC, Herdegen JJ, Perlis ML, et al. Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects. Int J Chron Obstruct Pulmon Dis 2011;6:625-35.
66. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med 2010;104:986-94.
67. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 2009;10:19-25.
68. Stege G, Heijdra YF, van den Elshout FJ, et al. Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 2010;104:518-24.
69. Nunes DM, Mota RM, Machado MO, Pereira ED, Bruin VM, Bruin PF. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res 2008;41:926-31.
70. Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13:79-84.
71. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-61.
72. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc (2003) 2012;52:e210-9.
73. Zheng JP, Wen FQ, Bai CX, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD 2013;10:164-71.
74. Lewis CA, Fergusson W, Eaton T, Zeng I, Kolbe J. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 2009;64:133-8.
75. Chaouat A, Weitzenblum E, Kessler R, et al. Sleep-related O2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Eur Respir J 1997;10:1730-5.
76. Ramsey R, Mehra R, Strohl KP. Variations in physician interpretation of overnight pulse oximetry monitoring. Chest 2007;132:852-9.
77. Becker HF, Piper AJ, Flynn WE, et al. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 1999;159:112-8.
78. Poongkunran C, Budhiraja R. Sleep board review question: nocturnal hypoxemia in COPD. Southwest J Pulm Crit Care 2013:12-4.
79. Mulloy E, Fitzpatrick M, Bourke S, O'Regan A, McNicholas WT. Oxygen desaturation during sleep and exercise in patients with severe chronic obstructive pulmonary disease. Respir Med 1995;89:193-8.
80. Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984;85:6-14.
81. Sajkov D, McEvoy RD. Obstructive sleep apnea and pulmonary hypertension. Prog Cardiovasc Dis 2009;51:363-70.
82. Perin C, Fagondes SC, Casarotto FC, Pinotti AF, Menna Barreto SS, Dalcin PeT. Sleep findings and predictors of sleep desaturation in adult cystic fibrosis patients. Sleep Breath 2012;16:1041-8.
83. McNicholas WT, Fitzgerald MX. Nocturnal deaths among patients with chronic bronchitis and emphysema. BMJ (Clin Res Ed) 1984;289:878.
84. Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986;41:846-54.
85. Fletcher EC, Donner CF, Midgren B, et al. Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. Chest 1992;101:649-55.
86. Lacasse Y, Sériès F, Vujovic-Zotovic N, et al. Evaluating nocturnal oxygen desaturation in COPD-revised. Respir Med 2011;105:1331-7.
87. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391-8.
88. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1:681-6.
89. Nisbet M, Eaton T, Lewis C, Fergusson W, Kolbe J. Overnight prescription of oxygen in long term oxygen therapy: time to reconsider the guidelines? Thorax 2006;61:779-82.
90. Fletcher EC, Luckett RA, Goodnight-White S, Miller CC, Qian W, Costarangos-Galarza C. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992;145:1070-6.
91. Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999;115:1338-45.
92. McNicholas WT, Calverley PM, Lee A, Edwards JC, Investigators TSSiC. Longacting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004;23:825-31.
93. Ryan S, Doherty LS, Rock C, Nolan GM, McNicholas WT. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration 2010;79:475-81.
94. Sposato B, Mariotta S, Palmiero G, Ricci A, Gencarelli G, Franco C. Oral corticosteroids can improve nocturnal isolated hypoxemia in stable COPD patients with diurnal PaO2 > 60 mmHg. Eur Rev Med Pharmacol Sci 2007;11:365-72.
95. Krachman SL, Chatila W, Martin UJ, et al. Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema. Chest 2005;128:3221-8.
96. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012;8:597-619.
97. O'Donoghue FJ, Catcheside PG, Ellis EE, et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. Eur Respir J 2003;21:977-84.
98. Midgren B, Hansson L. Changes in transcutaneous PCO2 with sleep in normal subjects and in patients with chronic respiratory diseases. Eur J Respir Dis 1987;71:388-94.
99. Sanders MH, Kern NB, Costantino JP, et al. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. Chest 1994;106:472-83.
100. Phan CQ, Tremper KK, Lee SE, Barker SJ. Noninvasive monitoring of carbon dioxide: a comparison of the partial pressure of transcutaneous and end-tidal carbon dioxide with the partial pressure of arterial carbon dioxide. J Clin Monit 1987;3:149-54.
101. Tarrega J, Anton A, Guell R, et al. Predicting nocturnal hypoventilation in hypercapnic chronic obstructive pulmonary disease patients undergoing longterm oxygen therapy. Respiration 2011;82:4-9.
102. Samolski D, Tárrega J, Antón A, et al. Sleep hypoventilation due to increased nocturnal oxygen flow in hypercapnic COPD patients. Respirology 2010;15:283-8.
103. Cooper CB, Howard P. An analysis of sequential physiologic changes in hypoxic cor pulmonale during long-term oxygen therapy. Chest 1991;100:76-80.
104. McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009;64:561-6.
105. Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995;152:538-44.
106. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation-a consensus conference report. Chest 1999;116:521-34.
107. Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002:CD002878.
108. Dellweg D, Schonhofer B, Haidl PM, et al. Short-term effect of controlled instead of assisted noninvasive ventilation in chronic respiratory failure due to chronic obstructive pulmonary disease. Respir Care 2007;52:1734-40.
109. Windisch W, Haenel M, Storre JH, Dreher M. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci 2009;6:72-6.
110. Murphy PB, Brignall K, Moxham J, Polkey MI, Davidson AC, Hart N. High pressure versus high intensity noninvasive ventilation in stable hypercapnic chronic obstructive pulmonary disease: a randomized crossover trial. Int J Chron Obstruct Pulmon Dis 2012;7:811-8.
111. Ekkernkamp E, Storre JH, Windisch W, Dreher M. Impact of intelligent volumeassured pressure support on sleep quality in stable hypercapnic chronic obstructive pulmonary disease patients: a randomized, crossover study. Respiration 2014;88:270-6.
112. Zamarrón C, García Paz V, Morete E, del Campo Matías F. Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis 2008;3:671-82.
113. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009;180:692-700.
114. Bednarek M, Plywaczewski R, Jonczak L, Zielinski J. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population study. Respiration 2005;72:142-9.
115. Pronzato C. Chronic obstructive pulmonary disease and obstructive sleep apnea. Association, consequences and treatment. Monaldi Arch Chest Dis 2010;73:155-61.
116. Teramoto S, Yamamoto H, Yamaguchi Y, Namba R, Ouchi Y. Obstructive sleep apnea causes systemic inflammation and metabolic syndrome. Chest. 2005;127:1074-5.
117. Budhiraja R, Parthasarathy S, Quan SF. Endothelial dysfunction in obstructive sleep apnea. J Clin Sleep Med 2007;3:409-15.
118. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002;122:1162-7.
119. Puig F, Rico F, Almendros I, Montserrat JM, Navajas D, Farre R. Vibration enhances interleukin-8 release in a cell model of snoring-induced airway inflammation. Sleep 2005;28:1312-6.
120. Kelly E, Owen CA, Pinto-Plata V, Celli BR. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013;7:57-64.
121. Budhiraja R, Kayyali US, Karamsetty M, et al. Estrogen modulates xanthine dehydrogenase/xanthine oxidase activity by a receptor-independent mechanism. Antioxid Redox Signal 2003;5:705-11.
122. Kayyali US, Budhiraja R, Pennella CM, et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol 2003;188:59-68.
123. Kasasbeh A, Kasasbeh E, Krishnaswamy G. Potential mechanisms connecting asthma, esophageal reflux, and obesity/sleep apnea complex-a hypothetical review. Sleep Med Rev 2007;11:47-58.
124. Scharf MB, Cohen AP. Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea. Ann Allergy Asthma Immunol 1998;81:279-87; quiz 287-90.
125. Larsson LG, Lindberg A, Franklin KA, Lundbäck B. Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population. Respir Med 2001;95:423-9.
126. Yigla M, Tov N, Solomonov A, Rubin AH, Harlev D. Difficult-to-control asthma and obstructive sleep apnea. J Asthma 2003;40:865-71.
127. Simard B, Turcotte H, Marceau P, et al. Asthma and sleep apnea in patients with morbid obesity: outcome after bariatric surgery. Obes Surg 2004;14:1381-8.
128. Kim KS, Kim JH, Park SY, et al. Smoking induces oropharyngeal narrowing and increases the severity of obstructive sleep apnea syndrome. J Clin Sleep Med 2012;8:367-74.
129. Shteinberg M, Weiler-Ravel D, Adir Y. [The overlap syndrome: obstructive sleep apnea and chronic obstructive pulmonary disease]. Harefuah 2009;148:333-6, 348.
130. Shepard JW, Garrison MW, Grither DA, Evans R, Schweitzer PK. Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. Am J Med 1985;78:28-34.
131. Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995;151:82-6.
132. Hawryłkiewicz I, Sliwiński P, Górecka D, Pływaczewski R, Zieliński J. Pulmonary haemodynamics in patients with OSAS or an overlap syndrome. Monaldi Arch Chest Dis 2004;61:148-52.
133. Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985;131:835-9.
134. Chaouat A, Weitzenblum E, Krieger J, et al. Prognostic value of lung function and pulmonary haemodynamics in OSA patients treated with CPAP. Eur Respir J 1999;13:1091-6.
135. Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case-control study. J Sleep Res 2007;16:128-34.
136. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010;182:325-31.
137. Stanchina ML, Welicky LM, Donat W, Lee D, Corrao W, Malhotra A. Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med 2013;9:767-72.
138. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996;109:380-6.
139. Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;3:737-47.
140. Mansfield D, Naughton MT. Effects of continuous positive airway pressure on lung function in patients with chronic obstructive pulmonary disease and sleep disordered breathing. Respirology 1999;4:365-70.
141. de Miguel J, Cabello J, Sánchez-Alarcos JM, Alvarez-Sala R, Espinós D, Alvarez-Sala JL. Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome. Sleep Breath 2002;6:3-10.
142. Peker Y, Hedner J, Johansson A, Bende M. Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnea patients on nasal CPAP treatment. Sleep 1997;20:645-53.
143. Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderateto-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010;35:132-7.
144. Teodorescu M, Xie A, Sorkness CA, et al. Effects of inhaled fluticasone on upper airway during sleep and wakefulness in asthma: a pilot study. J Clin Sleep Med 2014;10:183-93.
145. Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest 2008;133:1375-80.
146. López-Sánchez M, Muñoz-Esquerre M, Huertas D, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a low exercise capacity: a cross-sectional study. PLoS One 2013;8:e68034.
147. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
148. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
149. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92.
150. Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics. Sleep Med 2010;11:31-7.
151. Nichols DA, Allen RP, Grauke JH, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003;163:2323-9.
152. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-5.
153. Lo Coco D, Mattaliano A, Lo Coco A, Randisi B. Increased frequency of restless legs syndrome in chronic obstructive pulmonary disease patients. Sleep Med 2009;10:572-6.
154. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998;21:371-7.
155. Hoque R, Chesson AL. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010;6:79-83.
156. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-6.
157. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26:925-35.
158. Ulfberg J, Bjorvatn B, Leissner L, et al. Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 2007;8:768-72.
159. Phillips B, Hening W, Britz P, Mannino D. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest 2006;129:76-80.
160. Winkelman JW, Redline S, Baldwin CM, Resnick HE, Newman AB, Gottlieb DJ. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. Sleep 2009;32:772-8.
161. Saletu B, Anderer P, Saletu M, Hauer C, Lindeck-Pozza L, Saletu-Zyhlarz G. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002;3 Suppl:S35-42.
162. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7:545-52.
163. Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008;20:101-5.
164. Koo BB, Blackwell T, Ancoli-Israel S, et al. Association of incident cardiovascular disease with periodic limb movements during sleep in older men: outcomes of sleep disorders in older men (MrOS) study. Circulation 2011;124:1223-31.
165. Budhiraja R, Quan SF. Is restless legs syndrome associated with cardiovascular disease? Am J Med 2013;126:189-90.
166. Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ. The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med 2009;10:976-81.
167. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302.
168. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-52.
169. Montplaisir J, Fantini ML, Desautels A, Michaud M, Petit D, Filipini D. Longterm treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-11.
170. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30:249-55.
171. Birrell MA, Crispino N, Hele DJ, et al. Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol 2002;136:620-8.
172. Olson LG, Hensley MJ, Saunders NA. Ventilatory responsiveness to hypercapnic hypoxia during dopamine infusion in humans. Am Rev Respir Dis 1982;126:783-7.
173. Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013;14:675-84.
174. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a doubleblind, cross-over study. Neurology 2002;59:1573-9.
175. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-8.
176. Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011;18:69-78.
177. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med 2009;10:973-5.
178. Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006;19:487-93.
179. Mitchell UH. Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr Dis Treat 2011;7:251-7.
180. Cui Y, Wang Y, Liu Z. Acupuncture for restless legs syndrome. Cochrane Database Syst Rev 2008:CD006457.
181. Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, doubleblinded, sham-controlled trial. Chest 2009;135:74-80.
182. Mitchell UH, Myrer JW, Johnson AW, Hilton SC. Restless legs syndrome and near-infrared light: an alternative treatment option. Physiother Theory Pract 2011;27:345-51.